Standard

Understanding antideppressant discontinuation syndrome (asd) – bridging clinical and preclinical findings. / Забегалов, Константин; Колесникова, Татьяна; Хацко, Сергей; Волгин, Андрей; Яковлев, Олег; Амстиславская, Тамара; Алексеева, Полина; Мешалкина, Дарья Андреевна; Friend, Ashton; Bao, Wandong; Демин, Константин Андреевич; Калуев, Алан Валерьевич.

2018. Abstract from 5th Caribbean Biomedical Research Days CBRD-2018, Saint Lucia.

Research output: Contribution to conference › Abstract › peer-review

Harvard

Забегалов, К, Колесникова, Т, Хацко, С, Волгин, А, Яковлев, О, Амстиславская, Т, Алексеева, П, Мешалкина, ДА, Friend, A, Bao, W, Демин, КА & Калуев, АВ 2018, 'Understanding antideppressant discontinuation syndrome (asd) – bridging clinical and preclinical findings', 5th Caribbean Biomedical Research Days CBRD-2018, Saint Lucia, 16/01/18 - 18/01/18.

APA

Забегалов, К., Колесникова, Т., Хацко, С., Волгин, А., Яковлев, О., Амстиславская, Т., Алексеева, П., Мешалкина, Д. А., Friend, A., Bao, W., Демин, К. А., & Калуев, А. В. (2018). Understanding antideppressant discontinuation syndrome (asd) – bridging clinical and preclinical findings. Abstract from 5th Caribbean Biomedical Research Days CBRD-2018, Saint Lucia.

Vancouver

Забегалов К, Колесникова Т, Хацко С, Волгин А, Яковлев О, Амстиславская Т et al. Understanding antideppressant discontinuation syndrome (asd) – bridging clinical and preclinical findings. 2018. Abstract from 5th Caribbean Biomedical Research Days CBRD-2018, Saint Lucia.

Author

Забегалов, Константин ; Колесникова, Татьяна ; Хацко, Сергей ; Волгин, Андрей ; Яковлев, Олег ; Амстиславская, Тамара ; Алексеева, Полина ; Мешалкина, Дарья Андреевна ; Friend, Ashton ; Bao, Wandong ; Демин, Константин Андреевич ; Калуев, Алан Валерьевич. / Understanding antideppressant discontinuation syndrome (asd) – bridging clinical and preclinical findings. Abstract from 5th Caribbean Biomedical Research Days CBRD-2018, Saint Lucia.

BibTeX

@conference{d462e5b4fd8d4c4ca882e2b4fb42d387,
title = "Understanding antideppressant discontinuation syndrome (asd) – bridging clinical and preclinical findings",
abstract = "Antidepressant drugs are currently the most prescribed class of medications. In addition to treatment resistance and side effects of antidepressants, their clinical use is further complicated by antidepressant discontinuation syndrome (ADS). ADS typically occurs in patients following the interruption, dose reduction, or discontinuation of antidepressant drugs. ADS resembles a classical drug withdrawal syndrome, albeit differing from it because antidepressants generally do not induce addiction. The growing clinical importance and prevalence of ADS necessitate novel experimental (animal) models of this disorder. Currently available preclinical models of ADS are mainly rodent-based, and study mostly serotonergic antidepressants and their combinations. Here, we systematically assess clinical ADS symptoms and discuss current trends and challenges in the field of experimental (animal) models of ADS. We also outline basic mechanisms underlying ADS pathobiology, evaluate its genetic, pharmacological and environmental determinants, and suggest how using animal models of ADS may help generate important translational insights into human ADS condition, its prevention and therapy.",
author = "Константин Забегалов and Татьяна Колесникова and Сергей Хацко and Андрей Волгин and Олег Яковлев and Тамара Амстиславская and Полина Алексеева and Мешалкина, {Дарья Андреевна} and Ashton Friend and Wandong Bao and Демин, {Константин Андреевич} and Калуев, {Алан Валерьевич}",
year = "2018",
month = jun,
day = "16",
language = "English",
note = "5th Caribbean Biomedical Research Days CBRD-2018 ; Conference date: 16-01-2018 Through 18-01-2018",

}

RIS

TY - CONF

T1 - Understanding antideppressant discontinuation syndrome (asd) – bridging clinical and preclinical findings

AU - Забегалов, Константин

AU - Колесникова, Татьяна

AU - Хацко, Сергей

AU - Волгин, Андрей

AU - Яковлев, Олег

AU - Амстиславская, Тамара

AU - Алексеева, Полина

AU - Мешалкина, Дарья Андреевна

AU - Friend, Ashton

AU - Bao, Wandong

AU - Демин, Константин Андреевич

AU - Калуев, Алан Валерьевич

PY - 2018/6/16

Y1 - 2018/6/16

N2 - Antidepressant drugs are currently the most prescribed class of medications. In addition to treatment resistance and side effects of antidepressants, their clinical use is further complicated by antidepressant discontinuation syndrome (ADS). ADS typically occurs in patients following the interruption, dose reduction, or discontinuation of antidepressant drugs. ADS resembles a classical drug withdrawal syndrome, albeit differing from it because antidepressants generally do not induce addiction. The growing clinical importance and prevalence of ADS necessitate novel experimental (animal) models of this disorder. Currently available preclinical models of ADS are mainly rodent-based, and study mostly serotonergic antidepressants and their combinations. Here, we systematically assess clinical ADS symptoms and discuss current trends and challenges in the field of experimental (animal) models of ADS. We also outline basic mechanisms underlying ADS pathobiology, evaluate its genetic, pharmacological and environmental determinants, and suggest how using animal models of ADS may help generate important translational insights into human ADS condition, its prevention and therapy.

AB - Antidepressant drugs are currently the most prescribed class of medications. In addition to treatment resistance and side effects of antidepressants, their clinical use is further complicated by antidepressant discontinuation syndrome (ADS). ADS typically occurs in patients following the interruption, dose reduction, or discontinuation of antidepressant drugs. ADS resembles a classical drug withdrawal syndrome, albeit differing from it because antidepressants generally do not induce addiction. The growing clinical importance and prevalence of ADS necessitate novel experimental (animal) models of this disorder. Currently available preclinical models of ADS are mainly rodent-based, and study mostly serotonergic antidepressants and their combinations. Here, we systematically assess clinical ADS symptoms and discuss current trends and challenges in the field of experimental (animal) models of ADS. We also outline basic mechanisms underlying ADS pathobiology, evaluate its genetic, pharmacological and environmental determinants, and suggest how using animal models of ADS may help generate important translational insights into human ADS condition, its prevention and therapy.

M3 - Abstract

T2 - 5th Caribbean Biomedical Research Days CBRD-2018

Y2 - 16 January 2018 through 18 January 2018

ER -

ID: 33278362